AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02594176 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: applicable gel
Study NCT03568162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISB 830 - Part 1 Group 1
Description: Subcutaneous injection (SC) every 2 weeks
Study NCT03568162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISB 830 - Part 1 Group 2
Description: Subcutaneous injection (SC) every 2 weeks
Study NCT03568162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISB 830 - Part 1 Group 3
Description: Subcutaneous injection (SC) every 2 weeks
Study NCT03568162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Part 1 Group 4
Description: Subcutaneous injection (SC) every 2 weeks
Study NCT03568162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISB 830 - Part 2 Group 5
Description: Subcutaneous injection (SC) every 2 weeks
Study NCT03568162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Part 2 Group 6
Description: Subcutaneous injection (SC) every 2 weeks
Study NCT01793272 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: effect of pentoxifylline on ICSI outcome
Description: semen processing with pentoxifylline prior to ICSI
Study NCT02454907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Communication with the clinic
Description: Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
Study NCT02454907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication with the clinic
Description: Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
Study NCT03419520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Schoolchildren, parents and teachers from intervention schools, will regularly receive nutrition and healthy lifestyle guidelines performed by nutritionists. Moreover, workshops aimed to reinforce the healthy habits will also be held along the study.
Study NCT02484183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bubble continuous positive airway pressure (CPAP)
Description: This study will use an Airsep® oxygen concentrator and a Fisher \& Paykel Bubble CPAP (bCPAP) system to deliver bCPAP. The Airsep® machine is connected to the Fischer \& Paykel Bubble CPAP system and the CPAP delivers pressure and oxygen to the patient with appropriately sized masks and tubing. The Fischer \& Paykel Bubble CPAP system can deliver up to 10 centimeters (cm) water (H20) pressure. Since an oxygen concentrator is being used as the flow driver of this bubble CPAP system patients receiving CPAP will therefore also be receiving 6-8 liters per minute (LPM) of concentrated oxygen flow. Per manufacturer specifications the Airsep oxygen concentrator delivers 90-97% fractional inspired oxygen concentration at the 6-8 LPM flows required to generate 4-10 cm H20 pressure.
Study NCT04523948 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral and pharmacological support to reduce combustible tobacco use.
Description: Behavioral and pharmacological support to reduce combustible tobacco use.
Study NCT01180374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (about a quarter spoon of alcohol with no CBD).
Study NCT01180374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
Study NCT01180374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
Study NCT03728530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Breathing exercises
Description: In pursed lip exercise subject was guided to inhale through nose with mouth closed and exhale through pressed lips (pursed lips).~In Diaphragmatic breathing subject was instructed to place his one hand below the rib cage and the other hand on chest. The patient inhaled slowly so that stomach moves out against the hand. Tighten the stomach muscle while exhaling through pursed lip.~In powered breathing subject was to inhale and exhale forcefully with some movements like subject was instructed to inhale forcefully while moving his hands upward and exhale forcefully while moving hands downward.~These three exercise techniques were advised to each subject of experimental group. They have to practice these exercises 3-4 times a day with 10 repetitions each. These exercises can be performed in sitting position or in supine lying position. Subject can adopt any position in which he feels comfortable.
Study NCT03419611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Modal
Description: Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 3 times per week.
Study NCT03419611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Teacher provided with word list and teacher intervening as usual.
Study NCT03419611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Teacher provided with word list and teacher intervening as usual.
Study NCT03419611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Multi-Modal
Description: Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 5 times per week.
Study NCT04140838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Presentation of the general concept of ACT therapy. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis III. Session 5: Values and feelings. Session 6: Taking a direction. Session 7: Dare and change. Session 8: Ready to act with ACT.
Study NCT04140838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy for Depression (BATD)
Description: Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Collection of information regarding areas of activity and interaction contexts.~Session 2: Identification of information related to depressive behaviours. Session 3 Obtaining complementary information regarding the characteristics of the history of patient interactions and any contexts.~Session 4: Explanation of the hypotheses of problematic behaviour, its maintenance and change throughout the intervention.~Session 5: Once the 10 target activities have been identified, a record is made to track and their progress weekly.~Session 6: Discussion of what was obtained from the records in general and of the satisfaction obtained, and explanation of the contexts and reinforcers.~Session 7: Psycho-education Session 8: New behaviours, the goals achieved and the maintenance of the weekly activity are inquired about.
Study NCT04393623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal
Description: This cognitive reappraisal microintervention lasts 45-60 minutes.
Study NCT04393623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: This psychoeducational microintervention lasts 45-60 minutes.
Study NCT02176057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Study NCT04140838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.
Study NCT04140838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.
Study NCT03009409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Injectable Solution
Description: Once IV access has been obtained and a facemask has been applied for pre-oxygenation, the loading dose (0.25 mg/kg) of the study drug will be given over 60 seconds and the fixed infusion (5 mcg/kg/min to a maximum of 60 mg/hour) will be initiated by the anesthetist through the pump interface.~The study drug will be infused at a constant rate of 5 mcg/kg/min throughout the maintenance phase, until the end of the procedure (last suture), up to a maximum cumulative dose of 100 mg. If at any point the anesthesiologist feels that it is clinically necessary to reduce the amount of study drug infusion rate, they may opt to reduce the infusion rate by 50% (to 2.5 mcg/kg/min), or stop the infusion entirely.
Study NCT02329795 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: 60 Gy in 30 fractions, 5 days a week, modulated arc therapy.
Study NCT02329795 — intervention group
Intervention type: DRUG
Intervention: Temozolomide
Description: Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.
Study NCT04087863 — intervention group
Intervention type: OTHER
Intervention: Not applicable(observational study)
Description: Not applicable(observational study)
Study NCT02157363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repositioning
Study NCT02157363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single positioning
Study NCT02751892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active lifestyle programme
Description: The intervention is an activity lifestyle programme to increase physical activity behaviour post-intervention and to facilitate behaviour change maintenance at 3 months post-intervention.
Study NCT00250705 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole
Description: The initial dose depending on the weight of the patient will be as follows: \< 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; > 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study. All subjects initially received either a 5 or 10 mg/d (7.0 ± 2.6 mg/d) dose of aripiprazole. Thereafter the dose was individualized based on response and tolerance. Maximum dose was 20 mg.
Study NCT03846063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program
Description: The duration of the program is 12 weeks. Patients start the program within 7 days after of the surgery. Patients perform exercises independently at home using the tablet PC for instructions. The program includes strengthening and walking exercises based on increasing the muscle force, balance, and functionality. The exercises comprise movements that train abductors, flexors, and extensors of the affected hip. The content of the program is based on previous research and on guidelines from the American Association of Orthopaedic Surgeons. For the rest, the program is designed in line with the most recent guidelines from the Royal Dutch Society for Physical Therapy. Patients are asked to exercise at least 5 days a week, with rest days on Thursday and Sunday. Strengthening exercises will be performed 3 times a week. The instructions for the exercises will be provided by videos on the tablet PC, which patients have to imitate.
Study NCT01325038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isometric exercise
Description: Isometric exercise several times/week for three months
Study NCT01964872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877618: Part 1a
Description: Single ascending dose administered orally in liquid formulation (Formulation A). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
Study NCT01964872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877618: Part 1b
Description: Single dose administered orally in capsule formulation (Formulation B). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
Study NCT01964872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877618: Part 1c (optional)
Description: Single dose administered orally in an alternative capsule formulation (Formulation C). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
Study NCT04418154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
Study NCT04418154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
Study NCT01964872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877618: Part 2
Description: Single ascending dose administered orally in the formulation selected based on Parts 1a, 1b, and 1c (if applicable). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
Study NCT01964872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877618: Part 3
Description: Multiple ascending dose and formulation determined in Part 2 (not to exceed 600 mg) administered orally.
Study NCT01964872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877618: Part 4 (optional)
Description: Single dose and formulation as determined in Part 3 administered orally in older healthy male participant cohort.
Study NCT01964872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Parts 1a, 2, 3, and 4 (optional)
Description: Administered orally matched to study drug
Study NCT02332005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diepalrestat choline
Description: aldose reductase inhibitor
Study NCT02332005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01812473 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.
Study NCT01614184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein
Description: Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
Study NCT02246348 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: Recording Doppler ultrasound noninvasively from the right chest wall
Study NCT03009409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion in the ketamine group.
Study NCT02395666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Description: Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
Study NCT01824342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection
Study NCT04086160 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation device (Soterix Medical, New York, NY)
Description: Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.
Study NCT04086160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation device (Soterix Medical, New York, NY)
Description: Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.
Study NCT01471951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single embryo transfer in women at risk of multiple pregnancies
Description: Prospective study of single embryo transfers in selected women with good reproductive prognosis and high risk of multiple pregnancies in an IVF-ICSI program.. The day of the embryo transfer, the patients will be randomized by a computer application for morphological and morphometric embryo selection.
Study NCT00198536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecabet 2.83%
Study NCT00198536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecabet 3.70%
Study NCT00198536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT01710605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Circulating tumor cells counting at baseline
Description: 20 ml blood sample collected before randomization
Study NCT01710605 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Circulating tumor cells counting at baseline
Description: 20 ml blood sample collected before randomization
Study NCT02684396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648
Description: TAK-648 Solution
Study NCT02684396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-648 Placebo
Description: TAK-648 placebo-matching solution
Study NCT01291641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HMG-CoA Reductase Inhibitor
Description: During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.~Dosage regimen: following the package insert of each HMGCoA reductase inhibitor
Study NCT01291641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probucol
Description: In addition to the continued HMGCoA reductase inhibitor treatment, probucol is administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner)
Study NCT01291641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: In addition to the continued HMGCoA reductase inhibitor treatment, probucol and cilostazol are administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner) Cilostazol 100-mg tablet, twice daily by the oral route
Study NCT01089530 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Lifestyle intensive group
Description: hipocaloric diet smoking cessation physical exercise
Study NCT00605176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiquimod cream
Description: cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
Study NCT00605176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
Study NCT01514513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licefreee Spray
Description: Liquid applied to hair and left on for at least one hour once on day 1 and once on day 8 if live lice are present.
Study NCT01514513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% permethrin creme rinse
Description: Creme rinse applied to hair and rinsed off after 10 minutes once on day 1 and once on day 8 if live lice are present.
Study NCT01704534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28
Study NCT02123524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Study NCT02123524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05271227 — intervention group
Intervention type: OTHER
Intervention: Transthoracic echocardiography and Carotid artery doppler (PHILIPS HD11 XE ultrasound device) before and after PLR test.
Description: VTI-LVOT was measured by echo by placing the pulsed wave Doppler sample gate in the LVOT diameter in apical-5-chamber window. VTI-LVOT was obtained by manually tracing the Doppler velocity spectrum. LVOT velocity time integral was recorded before and after PLR test within 2 minutes. Carotid blood flow was measured by using two-dimensional image, the optimal image of the long-axis view was obtained at the common carotid artery. The sample volume was placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination,The angle correction cursor was placed parallel to the direction of blood flow. A PLR will be performed in 2 sequential steps, first step patient is seated in the semi recumbent position (45°) then using an automatic bed elevation technique, the lower limbs will be then raised to a 45° angle while the patient's trunk will be lowered in supine position. Thus, the angle between the trunk and the lower limbs will remain unchanged (135°).
Study NCT03147924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improvisation Group
Description: The aim of this pilot study is to investigate the effects of improvisational comedy in a group of help-seeking youth at risk of developing a range of mental health disorders, including social anxiety.